How Digitalization and QRM Maturity Are Reshaping Pharmaceutical Compliance into 2026
Henrik Johanning explains that quality risk management is moving from theory to real operational decisions. Companies now use risk-based thinking to guide facility upgrades, remediation, and capital investment instead of relying only on documentation. This shift follows ICH Q9 principles and makes risk management a core driver of compliance.
At the same time, EU GMP Annex 1 continues to reveal gaps in sterile manufacturing. Many facilities now realize procedural compliance is not enough. Therefore, companies invest in contamination control, HVAC upgrades, and water system improvements to stay compliant under stricter inspections.
Why Annex 11 and Annex 22 Are Increasing Digital GMP Expectations in Pharma Systems
Digital GMP expectations are rising under EU GMP Annex 11 and Annex 22. Annex 11 now demands stronger lifecycle control of computerized systems, data integrity, and continuous validation in complex IT environments. As a result, cloud and hybrid systems face higher regulatory scrutiny.
In addition, Annex 22 requires full governance of digital tools under the pharmaceutical quality system. This increases accountability and traceability from development to production. Therefore, digital transformation is now treated as a GMP compliance function, not just an IT project.
How Global Regulatory Convergence Is Changing Inspection and Supply Chain Strategy
Johanning highlights that regulatory convergence under EU GMP, ICH, and PIC/S is increasing global alignment. This reduces regional interpretation gaps but raises inspection consistency and expectations across all sites.
At the same time, geopolitical pressure and supply chain risks are forcing companies toward regionalization and dual sourcing. As a result, manufacturing strategy is now tightly linked with compliance and risk management.
Why AI Adoption in Pharma Still Faces Regulatory and Data Integrity Barriers
AI and analytics already improve deviation handling and process monitoring in pharma. However, broader adoption still faces regulatory and organizational barriers rather than technical ones.
Non-GMP-ready data and unclear validation expectations under Annex 11 slow down implementation. Therefore, companies need hybrid skills that combine quality, engineering, and data expertise.
What Pharma Manufacturers Must Prepare for in 2026 Under GMP and Digital Compliance Pressure
In 2026, digitalization will become a core part of GMP compliance. Annex 11 and Annex 22 will further tighten control over computerized systems, while legacy facilities must upgrade to meet new expectations.
Companies must move toward integrated programs that connect people, processes, and technology. Therefore, QRM, data integrity, and supply chain resilience must operate as one unified compliance system.
To manage increasing digital GMP expectations under Annex 11 and Annex 22, pharmaceutical companies need structured and compliant operational frameworks that connect technology with regulatory requirements.
Explore our Digital Solutions for GMP-Regulated Operations to support compliant digital transformation, strengthen data integrity, and align your systems with evolving FDA and EU GMP expectations.
Source: Pharmtech.Com